Drug therapy for acute myeloid leukemia

Martin S. Tallman(Memorial Sloan Kettering Cancer Center), Jacob M. Rowe(Technion – Israel Institute of Technology), D. Gary Gilliland(Brigham and Women's Hospital)

Blood

May 4, 2005

10.1182/blood-2005-01-0178

Cited by 670

Related Papers

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

|Blood|2016|5.9k

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

|Blood|2009|3.4k

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

|Blood|2022|3k

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

|Cancer Cell|2010|2.7k

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

|Journal of Clinical Oncology|2003|2.7k